Venetoclax: a review in relapsed/refractory chronic lymphocytic leukemia

<p>Compliance with Ethical Standards</p><p><em>Disclosure: </em>The preparation of this review was not supported by any external funding.</p><p><i>Conflicts of interest: Lesley Scott </i>is a salaried employees of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.</p><p><br></p><p></p><p>Additional information about this Adis Drug Evaluation can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here</b></a></p><p><br></p><p>Abstract</p><p></p><p>Venetoclax (Venclyxto^®; Venclexta^®) is a first-in-class, oral, selective B-cell lymphoma-2 (BCL-2) inhibitor. The drug is approved in numerous countries, including those of the EU and in the USA, for the treatment of adults with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL); the specific indication(s) for venetoclax may vary between individual countries. Venetoclax monotherapy or combination therapy with rituximab was an effective treatment, provided durable responses, and had a manageable safety profile in pivotal clinical trials in adults with RR CLL, including in patients with adverse prognostic factors. In combination with 6 cycles of rituximab, venetoclax (fixed 24 months’ treatment) was more effective than bendamustine plus rituximab (6 cycles) in prolonging progression-free survival (PFS) and inducing undetectable minimal residual disease (uMRD) in peripheral blood (PB) and bone marrow (BM), with these benefits sustained during 36 months’ follow-up. Hence, with its novel mechanism of action and convenient oral once-daily regimen, venetoclax monotherapy or fixed 24-month combination therapy with rituximab represents an important option for treating RR CLL, including in patients with del(17p) or <i>TP53</i> mutation and those failing a B cell receptor (BCR) inhibitor and/or chemotherapy.</p><p>© Springer Nature Switzerland AG 2019</p>